Atlas Trials

Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment

Clinical trial NCT05382052 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05382052
Sponsor
Fundación GECP
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Non Small Cell Lung Cancer Stage IIINeoadjuvant Treatment
Start date
2022-06-17
Primary completion
2026-12-30
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.